Predictability of antitumor efficacy of cetuximab plus irinotecan based on skin rash severity according to observation period in patients with metastatic colorectal cancer following failure of fluorouracil, irinotecan and oxaliplatin

Author：                                    

Publisher： Science Publishers

ISSN： 2049-9450

Source： Molecular and Clinical Oncology, Vol.3, Iss.5, 2015-01, pp. : 1029-1034

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil

By Pfeiffer Per   Nielsen Dorte   Yilmaz Mette   Iversen Anja   Vejlø Christian   Jensen Benny Vittrup  

Acta Oncologica, Vol. 46, Iss. 5, 2007-01 ,pp. : 697-701

Informa Healthcare

Access to resources Recommend Favorite

Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer

By Larsen Finn Ole   Pfeiffer Per   Nielsen Dorte   Skougaard Kristin   Qvortrup Camilla   Vistisen Kirsten   Fromm Anne-Lene   Jøørgensen Trine L.   Bjerregaard Jon K.   Hoegdall Estrid   Jensen Benny V.  

Acta Oncologica, Vol. 50, Iss. 4, 2011-05 ,pp. : 574-577

Informa Healthcare

Access to resources Recommend Favorite

Bevacizumab Plus Irinotecan–Based Therapy in Metastatic Colorectal Cancer Patients Previously Treated With Oxaliplatin-Based Regimens

By Yildiz Ramazan   Buyukberber Suleyman   Uner Aytug   Yamac Deniz   Coskun Ugur   Kaya Ali Osman   Ozturk Banu   Yaman Emel   Benekli Mustafa  

Cancer Investigation, Vol. 28, Iss. 1, 2010-01 ,pp. : 33-37

Informa Healthcare

Access to resources Recommend Favorite

Impact of third-line treatment with irinotecan plus cetuximab on non-tumor standardized uptake values in patients with metastatic colorectal cancer

By        

Oncology Letters, Vol. 4, Iss. 1, 2012-01 ,pp. : 131-134

Spandidos Publications

Access to resources Recommend Favorite

Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer

By Soeda Hiroshi   Shimodaira Hideki   Watanabe Mika   Suzuki Takao   Gamoh Makio   Mori Takahiro   Komine Keigo   Iwama Noriyuki   Kato Shunsuke   Ishioka Chikashi  

International Journal of Clinical Oncology, Vol. 18, Iss. 4, 2013-08 ,pp. : 670-677

Springer Publishing Company

Access to resources Recommend Favorite